PharmacoEconomics and Outcomes News

DTC advertising questioned among vulnerable populations
pp. 2-2(1)

Value of screening for proteinuria discussed in the US
pp. 2-2(1)

Guidance on use of newer antiepileptics released by UK NICE
pp. 2-2(1)

Salmeterol/fluticasone propionate single inhaler administration potentially cost saving
pp. 3-4(2)

Statin use excessive, inappropriate in Italy, says Health Minister
pp. 4-4(1)

Rational versus appropriate prescribing
pp. 4-4(1)

New guidelines for the treatment of acute otitis media (AOM) have been released by the American Academy of Pediatrics and the American Academy of Family Physicians.
pp. 4-4(1)

Acupuncture for chronic headache worth the extra cost to the UK NHS
pp. 5-5(1)

Counterfeit drugs: an increasing problem in the US
pp. 5-5(1)

Drotrecogin alfa good value for severe sepsis in Germany
pp. 5-5(1)

Adjusting for QOL not warranted in cancer intervention decisions
pp. 6-6(1)

Daily prophylactic medications were prescribed to just over 50% of paediatric patients presenting with migraine to a US paediatric neurology clinic between January and June 2001
pp. 6-6(1)

Effect of patient copayment rises on US clinic's drug costs
pp. 6-6(1)

Eptifibatide and tirofiban prescribed appropriately in Spain
pp. 6-6(1)

New research suggests that GPs are too willing to prescribe antidepressants
pp. 6-6(1)

PEG IFN--2a beats conventional therapy in hep C
pp. 7-7(1)

Who benefits from increased use of -blockers in heart failure?
pp. 7-7(1)

Antibacterial prescribing declining in the US
pp. 7-7(1)

Aspirin economically viable in Barrett's oesophagus?
pp. 8-8(1)

Racial disparities are observed in the use of colorectal diagnostic procedures in the US
pp. 8-8(1)

Adherence to antipsychotics low despite health, cost benefits
pp. 8-8(1)

Cost of epilepsy variable in Italy
pp. 9-9(1)

Individuals who live in US states where pharmacists can administer vaccinations have higher rates of influenza virus vaccination than individuals who live in states with no such policy
pp. 9-9(1)

The introduction of control measures did not influence antibacterial prescribing among primary-care physicians in Croatia
pp. 9-9(1)

Routine antiretroviral resistance testing of value in HIV infections
pp. 9-9(1)

Chemotherapy-induced nausea and vomiting costly in Germany
pp. 10-10(1)

Patients with knee osteoarthritis (OA) commonly use complementary medicines and therapies, but underuse physiotherapy
pp. 10-10(1)

Mental health service and psychiatric medication use appears to have been "modest" among New York residents in the 4-5 months following the terrorist attacks of 11 September 2001
pp. 10-10(1)

Increased antidepressant use among paediatric patients "worrying"
pp. 10-10(1)

Pioglitazone combination therapy good value in type 2 DM
pp. 11-11(1)

Out-of-pocket costs rise with severity of atopic dermatitis
pp. 11-11(1)

Spinal cord stimulation treatment worth it in refractory angina pectoris
pp. 11-11(1)

PD clinic improves symptoms, but raises costs in Germany
pp. 12-12(1)

Payment for living unrelated kidney donors cost saving
pp. 12-12(1)

Community pharmacist input as a member of a multidisciplinary team caring for patients with type 2 diabetes mellitus (DM) "has a positive impact on patient care" and clinical outcomes
pp. 12-12(1)

US Medicaid asthma DM pilot programme yields savings
pp. 12-12(1)

Preference for methotrexate in early RA increases
pp. 13-13(1)

Racial disparities evident in psychiatric care for US elderly
pp. 13-13(1)

CAM use frequent among patients with dystonia
pp. 13-13(1)

Paediatric dengue vaccine "highly cost-effective"
pp. 13-13(1)

QOL effects of sibutramine similar to placebo in obesity, diabetes
pp. 14-14(1)

Intranasal budesonide boosts QOL in paediatric allergic rhinitis
pp. 14-14(1)

Hysterectomy preferred in abnormal uterine bleeding
pp. 14-14(1)

A record £3.5 billion was spent by the British pharmaceutical industry in 2003 in the search for new medicines
pp. 15-15(1)

According to prominent figures in South Africa's medical industry, government plans to cut drug prices by 50% would not lead to real price declines of 40-70% as promised,
pp. 15-15(1)

Medical association welcomes Canadian govt funding initiative
pp. 15-15(1)

Drug spending rises in North America, Czech Republic
pp. 15-15(1)

Eli Lilly's erectile dysfunction (ED) treatment tadalafil [Cialis] has already captured a significant share of new US prescriptions in the class, despite being on the market for only 3 months.
pp. 15-15(1)

The US Centers for Medicare and Medicaid will provide expanded coverage for ocular photodynamic therapy with verteporfin [Visudyne] from 1 April 2003.
pp. 15-15(1)